Oncotarget Publishes New Data By Lantern Pharma, An AI Company Developing Cancer Therapies, Further Supporting Clinical Advancement Of LP-284, A Novel Synthetically Lethal Drug Candidate For Non-Hodgkin's Lymphomas
Portfolio Pulse from Happy Mohamed
Lantern Pharma published new data in Oncotarget supporting the clinical advancement of LP-284, a novel drug candidate for non-Hodgkin's lymphomas (NHL). The company plans to file an IND application with the FDA and initiate a Phase 1 trial for LP-284 in NHL during the second half of 2023.
June 26, 2023 | 12:30 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Lantern Pharma's new data supports the clinical advancement of LP-284 for non-Hodgkin's lymphomas, with a Phase 1 trial planned for the second half of 2023.
The new data published in Oncotarget demonstrates LP-284's antitumor potency for multiple non-Hodgkin's lymphomas, including mantle cell lymphoma (MCL) and double-hit lymphoma (DHL). This supports the clinical advancement of the drug candidate and may positively impact Lantern Pharma's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100